Drug Trial Radar · NCT04460547
Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic
Last checked: Nov 19, 2026Latest source record: Jul 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 25, 2020
Primary completion
Aug 15, 2020
Study completion Sep 20, 2020
Sponsor
- Lead sponsor
- Qassim UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 7, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year
Summary
As written by the sponsor on the registry.
On 11th of March 2020, WHO characterized COVID-19 infection as a Pandemic. After the COVID-19 infection is declared as a Pandemic there was an outburst regarding COVID-19 Research. The Research interest led to registration of Interventional and Observational studies world wide. There are constant efforts by Health care workers to seek information regarding the Interventional and Observational studies which can help in decision making regarding effective handling of COVID-19 infected patients. It is also important to track on the happenings in various frontiers of COVID-19 Research in view of historical interest and clinical relevance. This Observational Cross sectional study aims to explore the completed Researches in WHO-compliant registries to understand the trends of COVID-19 Research. This study aims to get a birds eye view of ongoing COVID-19 Research scenario worldwide. This study results can directly benefit the worldwide Academicians and Health Care Professionals to understand the ongoing COVID-19 Research trends.
Conditions
- COVID-19
Interventions
Convalescent Plasma TransfusionDrug
Convalescent Plasma Transfusion to COVID-19 infected patients.
HydroxychloroquineDrug
Hydroxychloroquine administration to COVID-19 infected patients.
DAS181Drug
DAS181 administration to COVID-19 infected patients.
IvermectinDrug
Ivermectin administration to COVID-19 infected patients.
Interferon Beta-1ADrug
Interferon Beta-1A administration to COVID-19 infected patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geographical distribution of the interventional studies after 11th of March 2020.Time frame: 15th of August 2020
- Geographical distribution of the Observational studies after 11th of March 2020.Time frame: 15th of August 2020
- Monthly Research study completion rate as per geographic distribution of the Research.Time frame: 15th of August 2020
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.